Key facts
- This page summarizes Lori Anne Kunkel's Form 4 filing for Enliven Therapeutics, Inc. (ELVN).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 09 Jun 2026, 16:49.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Sale
Sale
Sale
No transaction description listed
Additional SEC filing notes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Footnote F1
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026
Footnote F2
This transaction was executed in multiple trades at prices ranging from $33.7383 to $34.7358. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Footnote F3
The number of shares held reflects the transfer of 31,172 shares of Common Stock from Lori Kunkel Revocable Trust DTD 11/08/2018 Lori A Kunkel TTEE to the Reporting Person .
Footnote F4
This transaction was executed in multiple trades at prices ranging from $34.759 to $35.7574. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Footnote F5
This transaction was executed in multiple trades at prices ranging from $35.7595 to $35.9456. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Footnote F6
The shares were held by Lori Kunkel Revocable Trust DTD 11/08/2018 Lori A Kunkel TTEE.